Using different lung cancer models, we observed a remarkable synergistic control of lung tumor burden and metastatic progression in animals simultaneously treated with an aptamer against C5a (AON-D21) and an anti-PD-1 monoclonal antibody (13). Here, C5 is linked to lung cancer.